iTeos Therapeutics (ITOS) AI Stock Analysis

• Market Cap: $298.92M
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: N/A
• EPS Growth: 14.60%
• Country: US
• Employees: 173
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.80
• Shares Outstanding: 38,273,796
• 10 Day Avg. Volume: 2,461,453
• 30 Day Avg. Volume: 1,200,069
• PEG Ratio: -0.27
• Price to Book (P/B): 0.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.50
• Price Target Upside: 34.44% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

iTeos Therapeutics' overall stock score is primarily impacted by its financial difficulties, including declining profitability and negative cash flow. While technical analysis suggests some potential for upward momentum, the stock's valuation is a significant drawback due to its negative P/E ratio. The recent termination of a major collaboration adds further uncertainty. Investors should be cautious and consider the company's ability to improve its financial performance and strategic direction before investing.

Positive Factors

Cash Position

The company reported having $624 million, suggesting they are potentially well-capitalized to pursue their earlier programs.

Financial Position

The company's cash position is strong, with $624MM in cash expected to provide runway through 2027.

Strategic Review

Investors reacted positively to the news of belrestotug’s termination, with the stock showing an increase, likely due to the announcement of a strategic review to maximize shareholder value.

Negative Factors

Enterprise Value

The company still has a sizable negative enterprise value of over $200 million, despite the stock's positive movement.

Pipeline Development

There is low confidence that any early-stage immuno-oncology asset will add value for iTeos in the next year, as the investor bar for excitement is high.

Revenue Performance

During 1Q25, the company reported no revenue, compared to the consensus estimate of $1.8M, and a net loss of $0.80 per share.

iTeos Therapeutics Business Overview & Revenue Model

Company Description

iTeos Therapeutics (ITOS) is a biotechnology company focused on the discovery and development of innovative immuno-oncology treatments. The company operates within the pharmaceutical and healthcare sectors, aiming to harness the power of the immune system to provide transformative therapies for cancer patients. iTeos Therapeutics is dedicated to advancing a pipeline of drug candidates designed to improve and extend the lives of individuals battling cancer.

How the Company Makes Money

iTeos Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. Revenue streams include potential milestone payments and royalties from partnerships and collaborations with larger pharmaceutical companies. A significant partnership with GlaxoSmithKline (GSK) involves the development and commercialization of EOS-448, an anti-TIGIT antibody, which provides upfront payments, potential milestone payments, and future royalties on sales. Additionally, the company may generate revenue through licensing agreements and strategic collaborations, leveraging its expertise in immuno-oncology to expand its financial opportunities.

iTeos Therapeutics Financial Statement Overview

Summary

iTeos Therapeutics faces significant financial challenges. The income statement reflects stagnant revenue and declining profitability, leading to a score of 28.0. The balance sheet is relatively strong with a high equity ratio but shows declining assets and cash reserves, resulting in a score of 52.0. Cash flow issues are critical, with negative operating and free cash flows, scoring 40.0. Overall, financial performance is weak, with a need for improved revenue and cost management strategies.

Income Statement

iTeos Therapeutics has experienced significant volatility in its revenue and profitability. The TTM (Trailing-Twelve-Months) data shows a severe decline in profitability, with negative EBIT and net income margins. Revenue growth is stagnant, as current revenue matches the previous period. These trends reflect challenges in generating consistent revenue and managing costs, which is critical for long-term sustainability.

Balance Sheet

The balance sheet reveals a strong equity base, with a high equity ratio indicating stability. However, the debt-to-equity ratio is low, which is positive, though offset by declining total assets and stockholders' equity over recent periods. Despite these strengths, the decrease in cash reserves and equity suggests potential challenges in maintaining financial health if current trends continue.

Cash Flow

The cash flow situation is concerning with negative operating and free cash flows, indicating struggles in generating cash from operations. The free cash flow growth rate is negative, highlighting a worsening trend. Despite a positive financing cash flow, reliance on external funding is not a sustainable strategy for cash flow management.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
35.00M	35.00M	12.60M	267.63M	344.77M	0.00
	Gross Profit
34.69M	33.76M	11.70M	266.82M	344.16M	-535.00K
	EBIT
-152.32M	-159.53M	-151.10M	126.32M	244.90M	-45.24M
	EBITDA
-147.93M	-159.53M	-151.10M	148.38M	257.08M	-37.84M
	Net Income Common Stockholders
-130.81M	-134.41M	-112.64M	96.65M	214.52M	-38.03M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
449.14M	494.65M	531.92M	613.16M	848.54M	336.33M
	Total Assets
629.77M	686.98M	667.59M	754.99M	884.71M	344.56M
	Total Debt
5.82M	5.10M	6.06M	4.67M	5.34M	0.00
	Net Debt
-140.82M	-137.03M	-245.12M	-280.13M	-843.20M	-336.33M
	Total Liabilities
88.57M	96.68M	92.36M	91.66M	331.89M	21.36M
	Stockholders Equity
541.20M	590.29M	575.23M	663.33M	552.82M	323.20M
Cash Flow		Free Cash Flow
-100.33M	-99.81M	-106.72M	-112.13M	511.96M	-25.53M
	Operating Cash Flow
-99.55M	-98.18M	-103.76M	-111.19M	513.14M	-25.18M
	Investing Cash Flow
-13.86M	-131.15M	72.66M	-446.06M	-1.24M	-377.00K
	Financing Cash Flow
122.25M	122.24M	1.11M	1.98M	3.66M	340.34M

iTeos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.81
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITOS, the sentiment is Positive. The current price of 7.81 is above the 20-day moving average (MA) of 7.21, above the 50-day MA of 6.69, and below the 200-day MA of 9.24, indicating a neutral trend. The MACD of 0.29 indicates Negative momentum. The RSI at 59.72 is Neutral, neither overbought nor oversold. The STOCH value of 69.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ITOS.

iTeos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
ABEO	50 Neutral	$312.06M	―	-271.78%	―	-100.00%	30.33%
CDTX	48 Neutral	$330.73M	―	-299.58%	―	-99.35%	-260.33%
MNPR	48 Neutral	$227.24M	―	-54.27%	―	―	-35.23%
AVIR	47 Neutral	$234.49M	―	-30.47%	―	―	-22.66%
DSGN	47 Neutral	$199.26M	―	-22.59%	―	―	26.63%
ITOS	46 Neutral	$298.92M	―	-23.68%	―	―	14.60%

iTeos Therapeutics Corporate Events

iTeos Therapeutics Ends Collaboration with GSK

On May 13, 2025, iTeos Therapeutics and GlaxoSmithKline (GSK) announced the termination of their collaboration and license agreement, originally established in June 2021, following interim results from the GALAXIES Lung-201 study. The study, which assessed the combination of belrestotug and dostarlimab in non-small cell lung cancer, did not meet the criteria for progression-free survival improvements, leading to the decision to end the belrestotug development program. This termination will result in the cessation of financial obligations between the two companies and the end of new enrollment in ongoing trials. iTeos plans to explore strategic alternatives to maximize shareholder value, despite the disappointing trial results.

The most recent analyst rating on (ITOS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.

Spark’s Take on ITOS Stock

According to Spark, TipRanks’ AI Analyst, ITOS is a Neutral.

iTeos Therapeutics’ overall stock score is primarily impacted by its financial difficulties, including declining profitability and cash flow issues. The technical analysis suggests some potential for upward momentum, but the stock’s valuation is a significant drawback due to its negative P/E ratio. Investors should be cautious and consider the company’s ability to improve its financial performance before investing.

To see Spark’s full report on ITOS stock, click here.